Loading…
Employees: 48
Size iX Biopharma (42C.SI) is a Singapore Health Care company (Pharmaceuticals: Major) with a market value of $386M, the 122nd largest of 186 Singapore companies the cockpit tracks. Shares closed at S$0.45 on 6 Nov 2026.
Performance Over six months the shares gained 9.8%, against -21.0% for the median peer and -1.2% for the Singapore market (cap-weighted) — 6th highest of 20 in its peer set.
Growth Revenue fell 11.8% over the last twelve months (peer median +9.4%); the operating margin is -139.5% (peer median -6.4%).
Valuation It trades at 70.7× enterprise value to sales against a peer median of 5.8× (2nd most expensive of 17).
Capital Return on invested capital runs 133.1 points below its cost of capital (10.3% WACC).
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|---|
| Revenue | n/a | S$6.85M | S$7.77M | S$5.96M | S$5.91M |
| Revenue growth | — | -12% | +30% | +1% | — |
| Gross profit | n/a | S$2.43M | S$2.04M | S$1.05M | S$2.32M |
| EBITDA | n/a | -S$8.83M | -S$5.43M | -S$6.63M | -S$9.71M |
| Net income | n/a | -S$7.99M | -S$10.1M | -S$10.8M | -S$9.62M |
| Free cash flow | n/a | -S$8.07M | -S$4.59M | -S$7.09M | -S$8.63M |
| Capital expenditure | n/a | S$117,000 | S$201,000 | S$285,000 | S$695,000 |
| Total debt | S$5.80M | S$5.80M | S$5.90M | S$5.20M | S$4.34M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 42C.SI | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -13.5% | -12.6% | 10th lowest of 21 |
| 6-month return | +9.8% | -21.0% | 6th highest of 20 |
| Distance from 52-week high | -28.0% | -41.4% | 7th highest of 21 |
| Revenue growth (TTM) | -11.8% | +9.4% | 4th lowest of 18 |
| Operating margin | -139.5% | -6.4% | 3rd lowest of 18 |
| EV / Sales | 70.7× | 5.8× | 2nd most expensive of 17 |
| ROIC minus cost of capital | -133.1 pp | -8.2 pp | 2nd lowest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| iX Biopharma 42C.SI | Singapore | $386M | +10% | -12% | -140% | 70.7× | n/a | n/a |
| MapLight Therapeutics MPLT | United States | $385M | -75% | n/a | n/a | n/a | n/a | n/a |
| JCR Pharmaceuticals 4552.T | Japan | $383M | -11% | +3% | -14% | 2.9× | n/a | n/a |
| Tiansheng Pharmaceutical 002872.SZ | China | $392M | +15% | -1% | -13% | 5.2× | 23.2% | -15.7% |
| Heartseed 219A.T | Japan | $393M | +52% | +197% | 9% | 21.4× | 50.0% | +73.2% |
| SanBio 4592.T | Japan | $393M | -58% | n/a | n/a | n/a | n/a | n/a |
| Zota Health Care ZOTA.NS | India | $395M | -6% | +69% | -16% | 5.8× | n/a | n/a |
| Guizhou Yibai Pharmaceutical 600594.SS | China | $376M | -21% | -26% | -15% | 2.0× | 9.0% | -11.3% |
| Rezolute RZLT | United States | $375M | +21% | n/a | n/a | n/a | n/a | n/a |
| Tuoxin Pharmaceutical 301089.SZ | China | $400M | -22% | +17% | -20% | 5.8× | n/a | n/a |
| Unichem Laboratories UNICHEMLAB.NS | India | $373M | +28% | +9% | 5% | 1.5× | n/a | n/a |
| Chongqing Hifuture Information Technology 002168.SZ | China | $372M | -23% | +2% | -6% | 8.3× | 16.3% | -14.0% |
| Kwality Pharmaceuticals KPL.NS | India | $401M | +111% | +38% | 21% | 6.8× | n/a | n/a |
| Hyundai Bioscience 048410.KS | South Korea | $401M | -58% | +78% | -580% | 158.2× | n/a | n/a |
| Guangdong Lifestrong Pharmacy 301111.SZ | China | $401M | -16% | +7% | -2% | 7.9× | n/a | n/a |
| Anhui Fengyuan Pharmaceutical 000153.SZ | China | $372M | -17% | -24% | 3% | 1.1× | 4.2% | +3.1% |
| Avalo Therapeutics AVTX | United States | $372M | -68% | -87% | -154,844% | n/a | n/a | n/a |
| Shukra Pharmaceuticals SHUKRAPHAR.NS | India | $372M | n/a | +115% | 57% | 46.9× | n/a | n/a |
| JW Pharmaceutical 001060.KS | South Korea | $402M | -28% | +10% | 14% | 0.7× | -16.9% | +7.2% |
| Shandong Sinobioway Biomedicine 002581.SZ | China | $404M | -40% | +91% | -65% | 7.8× | n/a | n/a |
| Kingchem (Liaoning) Life Science 301509.SZ | China | $368M | -25% | +3% | 6% | 1.8× | 13.2% | +6.5% |